Actinium Pharmaceuticals (Delaware) Stock Forecast
NYSE: ATNMHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ATNM analyst consensus
Consensus (4 analysts)
none
Avg. price target
$3.60+233.33%
- Strong buy 1
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Actinium Pharmaceuticals (Delaware) (2026-10-09), 3 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $3.60, with a high estimate of $5.00 and a low estimate of $2.00. The average target implies upside of 233.3% from the current price of $1.08.
The spread between the highest and lowest targets is 150.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ATNM.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 25% |
| Buy | 2 | 50% |
| Hold | 1 | 25% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $2.00 | +85.19% |
| Average target | $3.60 | +233.33% |
| High target | $5.00 | +362.96% |